What the FDA labels say about taking them together
Asenapine and ciprofloxacin
Asenapine's FDA label (Secuado) of January 30, 2025 names ciprofloxacin in its drug interactions section; ciprofloxacin's label does not name asenapine itself but warns about its class (Atypical antipsychotics).
Check it at the source: the asenapine FDA label on DailyMed (effective January 31, 2025, Allergan, Inc.); the ciprofloxacin FDA label on DailyMed (effective March 2, 2026, Bayer HealthCare Pharmaceuticals Inc.).
What does the asenapine label say about ciprofloxacin?
Secuado label (Noven Therapeutics, LLC, January 30, 2025), drug interactionsFluvoxamine, ciprofloxacin, enoxacin CYP2D6 substrates and inhibitors Clinical Implication Asenapine may enhance the inhibitory effects of paroxetine on its own metabolism by CYP2D6.
Source: FDA drug label (Secuado, NDA212268), Noven Therapeutics, LLC, effective January 30, 2025 (SPL set 685eaf44-5944-4f38-afba-0a4fc0b3462b), via openFDA
Source: FDA drug label (SAPHRIS), NDA022117 (Abbvie), as published by Allergan, Inc., effective January 31, 2025 (SPL set 5429f134-839f-4ffc-9944-55f51238def8), via openFDA; the full label on DailyMed
What does the ciprofloxacin label say about asenapine?
Ciprofloxacin's label does not name asenapine itself; it warns about its class (Atypical antipsychotics):
Ciprofloxacin label, drug interactionsDrugs Known to Prolong QT Interval Avoid Use CIPRO may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) [see Warnings and Precautions ( 5.12 ) and Use in Specific Populations ( 8.5 )].
Ciprofloxacin label, warnings and precautionsAvoid CIPRO in patients with known prolongation of the QT interval, risk factors for QT prolongation or torsade de pointes (for example, congenital long QT syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics.
Source: FDA drug label (Cipro), Bayer HealthCare Pharmaceuticals Inc., effective March 2, 2026 (SPL set 888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Asenapine | Ciprofloxacin | |
|---|---|---|
| Labeled for | Schizophrenia, Bipolar disorder | Diarrhea, Urinary tract infections, Bacterial infections |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $2.63 per tablet 10 mg tablet sl | $0.123 per tablet 500 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once